博拓生物(688767) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was CNY 1,818,075,902.95, representing a 110.09% increase compared to CNY 865,371,453.85 in 2020[23]. - The net profit attributable to shareholders for 2021 was CNY 833,590,633.07, a 91.57% increase from CNY 435,146,719.99 in 2020[23]. - The net cash flow from operating activities for 2021 was CNY 908,123,247.63, up 103.58% from CNY 446,065,971.55 in 2020[23]. - The total assets at the end of 2021 reached CNY 2,431,508,922.58, a 283.57% increase from CNY 633,915,895.72 at the end of 2020[23]. - The net assets attributable to shareholders increased to CNY 2,107,098,138.47, a 374.42% rise from CNY 444,137,738.24 at the end of 2020[23]. - Basic earnings per share for 2021 were CNY 9.62, a 76.84% increase from CNY 5.44 in 2020[24]. - The net profit after deducting non-recurring gains and losses was CNY 825,500,564.78, reflecting a 92.13% increase from CNY 429,655,450.62 in 2020[23]. - The company's revenue increased by 110.09% from 2020 to 2021, reaching ¥1.818 billion, up from ¥865 million[57]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 30.00 CNY per 10 shares, totaling 320,000,001.00 CNY, which represents 38.39% of the net profit attributable to shareholders for 2021[5]. - The company has not proposed any capital reserve transfer to increase share capital or stock dividends for the current period[5]. - The company has a mixed compensation strategy, ensuring that cash distributions are at least 10% of the distributable profits for the year, provided there are no major investment plans[198]. - The cash dividend policy stipulates that for mature companies without major capital expenditures, cash dividends should constitute at least 80% of the profit distribution[199]. Research and Development - The research and development expenditure as a percentage of operating revenue was 3.41% in 2021, down 1.37 percentage points from 4.78% in 2020[24]. - R&D expenses for 2021 amounted to 61.92 million yuan, representing a 49.85% increase year-over-year[38]. - The company has a strong focus on R&D, with a total of 261 patent applications filed, of which 193 have been authorized[67]. - The company has developed multiple new technologies, including time-resolved immunofluorescence technology and multiplex detection technology, to enhance diagnostic capabilities[64]. - The company invested significantly in R&D for new products and technologies to meet diverse market demands[36]. - The company has obtained 33 new patents during the reporting period, including 27 domestic and 6 international patents[38]. Market Expansion and Sales Strategy - The company expanded its product lines in drug abuse testing and infectious disease testing, responding to the increased demand for COVID-19 testing[36]. - The company has entered new international markets including Russia, Australia, Switzerland, and Mexico, enhancing its global sales channels[39]. - The company has established a dual marketing system for domestic and international sales, with five regional sales managers responsible for different geographic areas in China[47]. - The company aims to enhance its core competitiveness by increasing R&D investment in molecular diagnostics and animal testing technology platforms[152]. - The company plans to accelerate the R&D and registration of COVID-19 products to meet the rising demand for home testing kits in major markets[156]. Risk Management - The company has identified significant risk factors that may adversely affect its operations, which are detailed in the management discussion section[4]. - The company emphasizes the importance of caution regarding forward-looking statements and investment risks[7]. - The company has a comprehensive risk management strategy in place to address potential adverse impacts on its business[4]. - The company faces risks related to new product development, including potential delays and registration challenges that could hinder market competitiveness and profitability[98]. - The company has a high customer concentration risk, with the top five customers accounting for 83.62% of sales, and reliance on the largest customer at 60.84% of total revenue, posing a threat to future orders[101]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance[6]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[8]. - The company received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. Employee and Management Information - The total number of employees in the parent company is 553, while the main subsidiaries have 69 employees, resulting in a total of 622 employees[190]. - The company has 23 retired employees for whom it bears expenses[190]. - The company emphasizes employee training, with key programs including a 12-month training for new graduates and a management training camp for middle-level managers[194]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to RMB 1,809.63 million[179]. - The actual remuneration for core technical personnel at the end of the reporting period was RMB 631.82 million[179]. Financial Position and Capital Management - Cash and cash equivalents increased to ¥1,367,736,419.05, representing a 423.69% increase compared to the previous period[138]. - Accounts receivable rose to ¥146,907,009.69, a 52.61% increase, attributed to significant business growth[138]. - Inventory increased to ¥141,704,232.16, reflecting a 53.38% growth due to expanded purchasing scale[138]. - The company reported a significant increase in accounts payable, which rose by 102.29% to ¥224,324,511.70, reflecting increased purchasing scale[139]. - The company’s deferred income tax assets increased by 97.69% to ¥3,007,309.76, due to growth in bad debt provisions and inventory depreciation[139].